Medicare Enrolled

Dr. Amy Cripps, M.D.

Medical Oncology · Dallas, TX
Low-engagement
7777 FOREST LN STE B242, Dallas, TX 75230
1473917062
In practice since 2006 (19 years)
NPI: 1689622557 verify on NPPES ↗
High
DATA COVERAGE
Data in 3 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Cripps from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Cripps? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Cripps

Dr. Amy Cripps is a medical oncology specialist in Dallas, TX, with 19 years of NPI registration.

Between the years covered by Open Payments, Dr. Cripps received a total of $6,330 from 58 pharmaceutical and/or device companies across 331 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in medical oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Cripps is High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 19 years in practice $6,330 industry payments

Industry Payment Transparency

Open Payments through 2024 ↗
$6,330
Total received (2018-2024)
Avg $1,055/year across 6 years
Top 43% in TX for medical oncology
58
Companies
331
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$5,582 (88.2%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$525 (8.3%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$224 (3.5%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$525
2022
$162
2021
$700
2020
$899
2019
$2,033
2018
$2,011

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
AstraZeneca Pharmaceuticals LP
$817
PFIZER INC.
$561
Novartis Pharmaceuticals Corporation
$473
Merck Sharp & Dohme Corporation
$448
E.R. Squibb & Sons, L.L.C.
$387
Foundation Medicine, Inc.
$369
Genentech USA, Inc.
$332
Clovis Oncology, Inc.
$208
Janssen Biotech, Inc.
$189
Celgene Corporation
$170
EMD Serono, Inc.
$147
GENZYME CORPORATION
$140
Exelixis Inc.
$138
Takeda Pharmaceuticals U.S.A., Inc.
$112
Amgen Inc.
$110
Incyte Corporation
$108
Boehringer Ingelheim Pharmaceuticals, Inc.
$103
Sirtex Medical Inc
$86
Ipsen Biopharmaceuticals, Inc
$71
Rigel Pharmaceuticals, Inc.
$67
Pharmacosmos Therapeutics Inc.
$62
Karyopharm Therapeutics Inc.
$60
ASD Specialty Healthcare, LLC
$60
Bayer HealthCare Pharmaceuticals Inc.
$57
Kite Pharma, Inc.
$57
TESARO, Inc.
$57
Lilly USA, LLC
$56
Taiho Oncology, Inc.
$54
Daiichi Sankyo Inc.
$52
Kyowa Kirin, Inc.
$52
Gilead Sciences, Inc.
$50
GlaxoSmithKline, LLC.
$48
Myovant Sciences Inc.
$48
Astellas Pharma US Inc
$38
Teva Pharmaceuticals USA, Inc.
$37
Sun Pharmaceutical Industries Inc.
$36
INSYS Therapeutics Inc
$35
ARRAY BIOPHARMA INC
$33
Alexion Pharmaceuticals, Inc.
$31
Pharmacyclics LLC, An AbbVie Company
$30
Mylan Institutional Inc.
$26
Pharmacyclics LLC, an AbbVie Company
$25
Regeneron Healthcare Solutions, Inc.
$24
AbbVie Inc.
$24
Puma Biotechnology, Inc.
$24
Deciphera Pharmaceuticals Inc.
$23
Adaptive Biotechnologies Corporation
$22
Lexicon Pharmaceuticals, Inc.
$20
Aurobindo Pharma USA, Inc.
$19
Acrotech Biopharma LLC
$18
Array BioPharma Inc.
$17
Dendreon Pharmaceuticals LLC
$17
Alnylam Pharmaceuticals Inc.
$17
AMAG Pharmaceuticals, Inc.
$15
Fortovia Therapeutics, Inc.
$14
Blueprint Medicines Corporation
$13
Seattle Genetics, Inc.
$12
MEDIVATION FIELD SOLUTIONS LLC
$10
Top 3 companies account for 29.2% of total payments
Associated products mentioned in payments ›
ABECMA · ADAKVEO · ADCETRIS · AFINITOR · ALIMTA · Abraxane · Alecensa · Avastin · BALVERSA · BENDEKA · BOSULIF · BRAFTOVI · Bavencio · Braftovi · CABLIVI · CALQUENCE · Cabometyx · DARZALEX · ELIQUIS · ELITEK · EMPLICITI · ERBITUX · ERLEADA · FARESTON · FERAHEME · FOUNDATIONACT · FOUNDATIONONE · Fulphila · GAVRETO · GAZYVA · GILOTRIF · GIVLAARI · IBRANCE · IMBRUVICA · IMFINZI · INJECTAFER · INLYTA · INREBIC · Imbruvica · JADENU · JAKAFI · JEVTANA · KEYTRUDA · KISQALI · Kadcyla · Kyprolis · LIBTAYO · LUTATHERA · LYNPARZA · Lonsurf · MARQIBO · MEKINIST · MONJUVI · MONOFERRIC · MVASI · NERLYNX · NINLARO · Neulasta · Nplate · ONTRUZANT · OPDIVO · ORGOVYX · Ogivri · PADCEV · PIQRAY · POTELIGEO · PROMACTA · PROVENGE · Perjeta · Pomalyst · QINLOCK · RYDAPT · Revlimid · Rubraca · SANCUSO · SANDOSTATIN · SANDOSTATIN LAR · SIR-Spheres Microspheres · SOLIRIS · SOMATULINE DEPOT · SUTENT · SYNDROS · Stivarga · TAGRISSO · TASIGNA · TECENTRIQ · Tavalisse · VENCLEXTA · VOTRIENT · Vectibix · XALKORI · XOSPATA · XPOVIO · XTANDI · Xermelo · YONSA · Yescarta · ZEJULA · Zevalin · clonoSEQ
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

Most payments (88%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.

Looking for a medical oncology specialist in Dallas?
Compare medical oncologists in the Dallas area by procedure volume, costs, and industry payment transparency.
Browse medical oncologists nearby

Geographic Context

Medical oncologists within 10 mi
92
Per 100K population
3.5
County median income
$74,149
Nearest hospital
MEDICAL CITY DALLAS HOSPITAL
0.0 mi

Data Sources

Provider Registry ✓ NPPES Weekly updates
Medicare Enrollment ✓ PECOS Monthly updates
Practice Data — No data N/A
Industry Payments ✓ Open Payments CY 2024
Disciplinary History — Not public N/A

This provider has data in 3 of 4 available federal datasets, with a Data Coverage level of High. This measures how much public data is available about a provider — not how good they are. How we calculate this →

Summary

Dr. Cripps is a medical oncology specialist, with low-engagement industry engagement, with 19 years of NPI registration.

This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →

Frequently Asked Questions

Does Dr. Cripps receive payments from pharmaceutical companies?
Yes. Dr. Cripps received a total of $6,330 from 58 companies across 331 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
What does Data Coverage mean?
Data Coverage (currently High for Dr. Cripps) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →

Explore related providers

Same specialty & city
Medical Oncologists in Dallas
Browse medical oncologists in Dallas ranked by procedure volume and transparency data.
Highest volume
Top Medical Oncologists in TX
Medical oncologists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Medical Oncologists in TX
Which TX medical oncologists receive the most from drug and device companies.
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
By company
PFIZER INC. Payments to Doctors
See all physicians who received payments from PFIZER INC.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →